Seven-Day Monitoring For Covaxin Shot Recipients

BENGALURU, 19 JAN 2021:

The National Centre for Disease Informatics and Research (NCDIR), a Bengaluru-based branch of ICMR, has been identified as the nodal centre to monitor Covaxin’s Phase 3 clinical trials.

In a video conference last week, state governments were directed to call and monitor the health of all Covaxin recipients for seven days from the day of immunisation. A report on their condition must also be sent to NCDIR.

A site each in Chamarajanagar, Davanagere, Hassan, Chikkamagaluru, Shivamogga and Ballari districts have been chosen to administer Covaxin.

Bharat BioTech, manufacturers of the vaccine, has said the common side effects include fever and abdominal pain, body ache, nausea and vomiting. The less common adverse effects are giddiness, tremors, cold, swelling around the injection site and sweating.

Dr Prashanth Mathur, director, NCDIR, said: “We are working out modalities with the state government to avoid duplication of efforts while monitoring Covaxin beneficiaries. We are planning work distribution to ensure the vaccine recipient is not burdened with multiple calls from different agencies. Covaxin beneficiaries are part of the trials.” Mathur said no beneficiary has reported side effects so far.The Times Of India